The Src-ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage

J Exp Med. 2023 Aug 7;220(8):e20220727. doi: 10.1084/jem.20220727. Epub 2023 May 9.

Abstract

Type I interferons are important antiviral cytokines, but prolonged interferon production is detrimental to the host. The TLR3-driven immune response is crucial for mammalian antiviral immunity, and its intracellular localization determines induction of type I interferons; however, the mechanism terminating TLR3 signaling remains obscure. Here, we show that the E3 ubiquitin ligase ZNRF1 controls TLR3 sorting into multivesicular bodies/lysosomes to terminate signaling and type I interferon production. Mechanistically, c-Src kinase activated by TLR3 engagement phosphorylates ZNRF1 at tyrosine 103, which mediates K63-linked ubiquitination of TLR3 at lysine 813 and promotes TLR3 lysosomal trafficking and degradation. ZNRF1-deficient mice and cells are resistant to infection by encephalomyocarditis virus and SARS-CoV-2 because of enhanced type I interferon production. However, Znrf1-/- mice have exacerbated lung barrier damage triggered by antiviral immunity, leading to enhanced susceptibility to respiratory bacterial superinfections. Our study highlights the c-Src-ZNRF1 axis as a negative feedback mechanism controlling TLR3 trafficking and the termination of TLR3 signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents
  • COVID-19*
  • Genes, src
  • Interferon Type I*
  • Mice
  • SARS-CoV-2
  • Toll-Like Receptor 3

Substances

  • Antiviral Agents
  • Interferon Type I
  • TLR3 protein, mouse
  • Toll-Like Receptor 3
  • ZNRF1 protein, mouse